Logo image of ANVS

ANNOVIS BIO (ANVS) Stock Fundamental Analysis

USA - NYSE:ANVS - US03615A1088 - Common Stock

2.27 USD
+0.01 (+0.44%)
Last: 10/8/2025, 8:27:34 PM
2.29 USD
+0.02 (+0.88%)
After Hours: 10/8/2025, 8:27:34 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ANVS. ANVS was compared to 536 industry peers in the Biotechnology industry. ANVS has a great financial health rating, but its profitability evaluates not so good. ANVS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ANVS had negative earnings in the past year.
In the past year ANVS has reported a negative cash flow from operations.
In the past 5 years ANVS always reported negative net income.
In the past 5 years ANVS always reported negative operating cash flow.
ANVS Yearly Net Income VS EBIT VS OCF VS FCFANVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

ANVS's Return On Assets of -141.04% is on the low side compared to the rest of the industry. ANVS is outperformed by 83.96% of its industry peers.
ANVS has a worse Return On Equity (-165.08%) than 64.37% of its industry peers.
Industry RankSector Rank
ROA -141.04%
ROE -165.08%
ROIC N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANVS Yearly ROA, ROE, ROICANVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

ANVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANVS Yearly Profit, Operating, Gross MarginsANVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

ANVS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ANVS has been increased compared to 5 years ago.
There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANVS Yearly Shares OutstandingANVS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANVS Yearly Total Debt VS Total AssetsANVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -3.71, we must say that ANVS is in the distress zone and has some risk of bankruptcy.
ANVS's Altman-Z score of -3.71 is in line compared to the rest of the industry. ANVS outperforms 43.66% of its industry peers.
There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.71
ROIC/WACCN/A
WACCN/A
ANVS Yearly LT Debt VS Equity VS FCFANVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

ANVS has a Current Ratio of 7.65. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.65, ANVS is doing good in the industry, outperforming 72.01% of the companies in the same industry.
ANVS has a Quick Ratio of 7.65. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.65, ANVS is in the better half of the industry, outperforming 72.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.65
Quick Ratio 7.65
ANVS Yearly Current Assets VS Current LiabilitesANVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

ANVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.45%, which is quite impressive.
EPS 1Y (TTM)52.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.24% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.28%
EPS Next 2Y15.17%
EPS Next 3Y11.78%
EPS Next 5Y12.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANVS Yearly Revenue VS EstimatesANVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M
ANVS Yearly EPS VS EstimatesANVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANVS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANVS Price Earnings VS Forward Price EarningsANVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANVS Per share dataANVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.17%
EPS Next 3Y11.78%

More info and screens

0

5. Dividend

5.1 Amount

ANVS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANNOVIS BIO

NYSE:ANVS (10/8/2025, 8:27:34 PM)

After market: 2.29 +0.02 (+0.88%)

2.27

+0.01 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners14.49%
Inst Owner Change0%
Ins Owners14.81%
Ins Owner Change3.97%
Market Cap44.24M
Analysts80
Price Target14.03 (518.06%)
Short Float %9.57%
Short Ratio6.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.01%
Min EPS beat(2)11.97%
Max EPS beat(2)22.06%
EPS beat(4)2
Avg EPS beat(4)-18.58%
Min EPS beat(4)-80.79%
Max EPS beat(4)22.06%
EPS beat(8)4
Avg EPS beat(8)-6.42%
EPS beat(12)7
Avg EPS beat(12)-18.16%
EPS beat(16)8
Avg EPS beat(16)-29.65%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.51%
PT rev (3m)-26.67%
EPS NQ rev (1m)1.72%
EPS NQ rev (3m)12.31%
EPS NY rev (1m)8.36%
EPS NY rev (3m)25.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.41
P/tB 2.41
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)-1.23
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0
BVpS0.94
TBVpS0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -141.04%
ROE -165.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.65
Quick Ratio 7.65
Altman-Z -3.71
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y30.28%
EPS Next 2Y15.17%
EPS Next 3Y11.78%
EPS Next 5Y12.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.18%
EBIT Next 3Y-44.37%
EBIT Next 5Y-5.41%
FCF growth 1Y14.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.32%
OCF growth 3YN/A
OCF growth 5YN/A